Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Share-based Compensation (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Share-based Compensation for 16 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 16.27% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.2 million through Dec 2025, down 42.21% year-over-year, with the annual reading at $17.2 million for FY2025, 42.21% down from the prior year.
  • Share-based Compensation hit $3.8 million in Q4 2025 for Ironwood Pharmaceuticals, up from $3.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.7 million in Q4 2023 to a low of $3.6 million in Q3 2025.
  • Historically, Share-based Compensation has averaged $6.4 million across 5 years, with a median of $6.4 million in 2021.
  • Biggest five-year swings in Share-based Compensation: soared 43.84% in 2022 and later crashed 56.63% in 2025.
  • Year by year, Share-based Compensation stood at $6.1 million in 2021, then rose by 19.72% to $7.3 million in 2022, then grew by 19.38% to $8.7 million in 2023, then tumbled by 47.54% to $4.6 million in 2024, then dropped by 16.27% to $3.8 million in 2025.
  • Business Quant data shows Share-based Compensation for IRWD at $3.8 million in Q4 2025, $3.6 million in Q3 2025, and $4.5 million in Q2 2025.